3. 40 countries New sites added to regions since we began:  CCASAnet – Mexico  West Africa – Nigeria  Southern Africa – Zambia  Asia – Vietnam

4. NA-ACCORD – When to start CCASAnet – Mortality; site assessments East Africa – LTFU Central Africa – Discordant couples; ETOH Southern Africa – IRIS, Peds ART outcomes West Africa – pediatric mortality on ART Asia – ART and anemia (1 st global concept); HBV & HCV impact on HIV outcomes

5. Cancer, Heart and Kidney disease - Understanding the impact on HIV (CHK-UP on HIV) Customized Computer Software for EMR (CCASA) Increased Analytic Capacity in REACT (East and Southern Africa) Open MRS System Development (East Africa) IeDEA adds Malaria Malaria surveillance at “Network Trial sites” with epidemiology led by IeDEA investigators Collaboration with DMID *American Recovery and Reinvestment Act of 2009 ARRA* Initiatives

6. NIH/PEPFAR Supplements Implementation Science –Inform programs: efficiency, effectiveness –Impact evaluation Limited Competition –Current grantees; no limit to # of applications –Research at PEPFAR funded sites (direct/indirect) 5-page concepts 1-year projects only (potential for carry forward x1 yr)

8. IeDEA II (funding starts 2011) Enhance analytical capacity - complex analysis Manage impact of loss to follow-up Selected enhancements of data: adverse events, mortality, risk behaviors Strengthen links to other programs: Cancer, TB, PMTCT, Pediatric to Adult Expand to cover the “Big 3 +” (HIV, Malaria, TB, hepatitis)

9. IeDEA RFA what is knowable (today that is) Dates to keep in mind Published mid July 2010 Due mid November 2010 Reviewed winter 2010/2011 Awarded spring/summer 2011 Funding Slightly more money overall Same institutes (at least) NIAID, NCI, NICHD New Format

10. Background and Significance Research Strategy a.Significance b.Innovation c.Approach Preliminary Studies for New Applications Progress Report for Renewal/Revision Research Design and Methods Preliminary Studies/Progress Report Old ApplicationNew Application RESTRUCTURED RESEARCH PLAN

11. Other Sections Personal Statement: Tell us why your experience and qualifications make you particularly well-suited for your role in the project Publications: Will be encouraged to include no more than 15 using recency, importance to the field, and/or relevancy to the application Total Biosketch will still be limited to 4 pages, including the education table at the top Environment - Address how the scientific environment will contribute to probability of success of the project, unique features of the environment, etc. For ESIs, provide a description of the institutional investment in the success of the investigator.

12. http://odoerdb2.od.nih.gov/PeerReview/Revised_Page_Limits.pdf